325 related articles for article (PubMed ID: 37766573)
21. Niacin and Chronic Kidney Disease.
Taketani Y; Masuda M; Yamanaka-Okumura H; Tatsumi S; Segawa H; Miyamoto K; Takeda E; Yamamoto H
J Nutr Sci Vitaminol (Tokyo); 2015; 61 Suppl():S173-5. PubMed ID: 26598845
[TBL] [Abstract][Full Text] [Related]
22. Klotho, phosphate and FGF-23 in ageing and disturbed mineral metabolism.
Kuro-o M
Nat Rev Nephrol; 2013 Nov; 9(11):650-60. PubMed ID: 23774819
[TBL] [Abstract][Full Text] [Related]
23. Effects of calcium-containing phosphate binders on cardiovascular events and mortality in predialysis CKD stage 5 patients.
Tsai PH; Chung CH; Chien WC; Chu P
PLoS One; 2020; 15(10):e0241435. PubMed ID: 33125428
[TBL] [Abstract][Full Text] [Related]
24. FGF23 and Phosphate-Cardiovascular Toxins in CKD.
Vogt I; Haffner D; Leifheit-Nestler M
Toxins (Basel); 2019 Nov; 11(11):. PubMed ID: 31698866
[TBL] [Abstract][Full Text] [Related]
25. Characteristics of coronary artery disease in chronic kidney disease.
Fujii H; Kono K; Nishi S
Clin Exp Nephrol; 2019 Jun; 23(6):725-732. PubMed ID: 30830548
[TBL] [Abstract][Full Text] [Related]
26. Phosphate toxicity and vascular mineralization.
Razzaque MS
Contrib Nephrol; 2013; 180():74-85. PubMed ID: 23652551
[TBL] [Abstract][Full Text] [Related]
27. Phosphate in early chronic kidney disease: associations with clinical outcomes and a target to reduce cardiovascular risk.
Toussaint ND; Pedagogos E; Tan SJ; Badve SV; Hawley CM; Perkovic V; Elder GJ
Nephrology (Carlton); 2012 Jul; 17(5):433-44. PubMed ID: 22574672
[TBL] [Abstract][Full Text] [Related]
28. [Vascular Calcification - Pathological Mechanism and Clinical Application - . Vascular calcification in chronic kidney disease-mineral and bone disorder (CKD-MBD)].
Omata M; Fukagawa M; Kakuta T
Clin Calcium; 2015 May; 25(5):645-53. PubMed ID: 25926567
[TBL] [Abstract][Full Text] [Related]
29. Calcitriol Accelerates Vascular Calcification Irrespective of Vitamin K Status in a Rat Model of Chronic Kidney Disease with Hyperphosphatemia and Secondary Hyperparathyroidism.
McCabe KM; Zelt JG; Kaufmann M; Laverty K; Ward E; Barron H; Jones G; Adams MA; Holden RM
J Pharmacol Exp Ther; 2018 Sep; 366(3):433-445. PubMed ID: 29903718
[TBL] [Abstract][Full Text] [Related]
30. Serum Calcification Propensity and Coronary Artery Calcification Among Patients With CKD: The CRIC (Chronic Renal Insufficiency Cohort) Study.
Bundy JD; Cai X; Scialla JJ; Dobre MA; Chen J; Hsu CY; Leonard MB; Go AS; Rao PS; Lash JP; Townsend RR; Feldman HI; de Boer IH; Block GA; Wolf M; Smith ER; Pasch A; Isakova T;
Am J Kidney Dis; 2019 Jun; 73(6):806-814. PubMed ID: 30935773
[TBL] [Abstract][Full Text] [Related]
31. Pathophysiology and treatment of cardiovascular disease in pediatric chronic kidney disease.
Khouzam N; Wesseling-Perry K
Pediatr Nephrol; 2019 Jan; 34(1):1-10. PubMed ID: 28939921
[TBL] [Abstract][Full Text] [Related]
32. Phosphate is a vascular toxin.
Shroff R
Pediatr Nephrol; 2013 Apr; 28(4):583-93. PubMed ID: 23161206
[TBL] [Abstract][Full Text] [Related]
33. Phosphate binders prevent phosphate-induced cellular senescence of vascular smooth muscle cells and vascular calcification in a modified, adenine-based uremic rat model.
Yamada S; Tatsumoto N; Tokumoto M; Noguchi H; Ooboshi H; Kitazono T; Tsuruya K
Calcif Tissue Int; 2015 Apr; 96(4):347-58. PubMed ID: 25511229
[TBL] [Abstract][Full Text] [Related]
34. Genetic Evidence for a Causal Role of Serum Phosphate in Coronary Artery Calcification: The Rotterdam Study.
Campos-Obando N; Bosman A; Kavousi M; Medina-Gomez C; van der Eerden BCJ; Bos D; Franco OH; Uitterlinden AG; Zillikens MC
J Am Heart Assoc; 2022 Aug; 11(15):e023024. PubMed ID: 35904204
[TBL] [Abstract][Full Text] [Related]
35. Fibroblast growth factor-23 helps explain the biphasic cardiovascular effects of vitamin D in chronic kidney disease.
Hu P; Xuan Q; Hu B; Lu L; Wang J; Qin YH
Int J Biol Sci; 2012; 8(5):663-71. PubMed ID: 22606047
[TBL] [Abstract][Full Text] [Related]
36. High phosphate-induced downregulation of PPARγ contributes to CKD-associated vascular calcification.
Liu L; Liu Y; Zhang Y; Bi X; Nie L; Liu C; Xiong J; He T; Xu X; Yu Y; Yang K; Gu J; Huang Y; Zhang J; Zhang Z; Zhang B; Zhao J
J Mol Cell Cardiol; 2018 Jan; 114():264-275. PubMed ID: 29197521
[TBL] [Abstract][Full Text] [Related]
37. The role of phosphate-containing medications and low dietary phosphorus-protein ratio in reducing intestinal phosphorus load in patients with chronic kidney disease.
Li J; Wang L; Han M; Xiong Y; Liao R; Li Y; Sun S; Maharjan A; Su B
Nutr Diabetes; 2019 Apr; 9(1):14. PubMed ID: 30944300
[TBL] [Abstract][Full Text] [Related]
38. Gastrointestinal phosphate handling in CKD and its association with cardiovascular disease.
Weinman EJ; Light PD; Suki WN
Am J Kidney Dis; 2013 Nov; 62(5):1006-11. PubMed ID: 23769135
[TBL] [Abstract][Full Text] [Related]
39. Severe asymptomatic coronary obstruction in chronic hemodialysed patient - a case report.
Voiculeț C; Zara O; Văcăroiu I; Bogeanu C; Tiron T; Turcu F; Aron G; Ciocâlteu A
J Med Life; 2016; 9(4):424-428. PubMed ID: 27928449
[No Abstract] [Full Text] [Related]
40. Predictors of coronary artery calcification and its association with cardiovascular events in patients with chronic kidney disease.
Wang XR; Yuan L; Shi R; Li H; Wang DG; Wu YG
Ren Fail; 2021 Dec; 43(1):1172-1179. PubMed ID: 34315328
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
